Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (RECLAIM)
Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study
Sponsor: Mallinckrodt
Terminated
Study reached halfway point in approximately one year time period and was halted to analyze data.
Other terminated trials from Mallinckrodt
Other Multiple Sclerosis trials with similar outcome
This PHASE2/PHASE3 trial investigates Multiple Sclerosis and is currently terminated or withdrawn. Mallinckrodt leads this study, which shows 10 recorded versions since 2009 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2_PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
- Neurologique Foundation, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .